




PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

8th August 2018 - New research

GARCINOL - A FUTURE MAO INHIBITOR FOR PARKINSON'S DISEASE

MAO inhibitors are often prescribed for Parkinson's Disease. MAO inhibitors help to maintain dopamine levels by inhibiting the enzyme Monoamine Oxidase (MAO). It is primarily low dopamine levels that cause Parkinson's Disease. The main MAO inhibitors in use are selegiline, rasagiline and safinamide. For more information go to selegiline <https://www.rxlist.com/eldepryl-drug.htm>, rasagiline <https://www.rxlist.com/azilect-drug.htm> and safinamide <https://www.rxlist.com/xadago-drug.htm> Researchers have assessed Garcinol, which originates from plant species. For more information go to : garcinol <https://www.drugs.com/npp/garcinol.html>



The present study identified Garcinol as a potential candidate in the treatment of Parkinson's Disease by virtue of its exorbitant MAO-B inhibitory potential. The inhibitory potential is comparable to the known MAO-B inhibitors, which was evaluated using molecular docking technique.

Additionally, Garcinol was found to have potential as a COMT inhibitor, which the existing MAO inhibitors don't have. COMT inhibitors are another type of Parkinson's Disease drug. It was also found to have known antioxidant and anti-inflammatory potential.

Reference : Medical Hypotheses [2018] 117 : 54-58 (M.K.Mazumder, R.Paul, B.C.Phukan, A.Dutta, J.Chakrabarty, P.Bhattacharya, A.Borah)

Complete abstract : <http://www.ncbi.nlm.nih.gov/pubmed/30077198>

<http://www.viartis.net/parkinsons.disease/news/180808.pdf>

mail@viartis.net

©2018 Viartis